HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VRDN
Viridian Therapeutics, Inc.
There isn't enough reported data to score VRDN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VRDN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
VRDN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VRDN PE Valuation
VRDN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VRDN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect VRDN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
VRDN has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus VRDN down 190%.
VRDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.86 | +$0.44 |
| Q2 2025 | -$4.65 | -$0.41 |
| Q1 2025 | -$4.44 | +$0.05 |
| Q4 2024 | -$4.16 | +$1.15 |
| Q3 2024 | -$4.30 | +$0.82 |
| Q2 2024 | -$4.24 | +$0.65 |
| Q1 2024 | -$4.49 | +$0.19 |
| Q4 2023 | -$5.31 | -$1.26 |
VRDN is still losing money, but far less than before: $3.86 per share over the past year, against $31.75 at its worst in mid-2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VRDN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over VRDN on profitability, with a higher operating margin.
VRDN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.8M | -64% |
| Q2 2026 | $284K | +279% |
| Q1 2026 | $141K | +96% |
| Q4 2025 | $132K | +83% |
| Q3 2025 | $70.6M | +81958% |
| Q2 2025 | $75K | +4.2% |
| Q1 2025 | $72K | 0% |
| Q4 2024 | $72K | 0% |
VRDN's revenue has slid since its 2025 peak: $26M last quarter, down 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -402% | -345 points |
| Q2 2026 | -44461% | +97895 points |
| Q1 2026 | -82389% | +47980 points |
| Q4 2025 | -92992% | +28497 points |
| Q3 2025 | -57% | +97013 points |
| Q2 2025 | -142356% | -42096 points |
| Q1 2025 | -130369% | -52735 points |
| Q4 2024 | -121489% | -22214 points |
VRDN's operating margin was −402% last quarter, down 345 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VRDN on cash generation, producing positive trailing cash flow while its opponent burns cash.
VRDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$93.1M | -$8.4M |
| Q2 2026 | -$106.6M | -$31.2M |
| Q1 2026 | -$119.7M | -$26.9M |
| Q4 2025 | -$24M | +$49.5M |
| Q3 2025 | -$84.7M | -$16.7M |
| Q2 2025 | -$75.4M | -$29.3M |
| Q1 2025 | -$92.7M | -$47.5M |
| Q4 2024 | -$73.4M | -$35.4M |
VRDN has burned cash in almost every quarter: −$343M over the past year, against −$326M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VRDN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VRDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +266K shares |
| 1 year | +19% | +18.1M shares |
| 3 years | +163% | +70.3M shares |
| 5 years | +2953% | +110M shares |
VRDN has 114M diluted shares, up 19% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VRDN Net Leverage
VRDN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VRDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.2 | Neutral |
| Stochastic | 91.0 | Overbought |
VRDN's weekly RSI is 69 (neutral) and its Stochastic is 91 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VRDN PE vs Healthcare Sector
VRDN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VRDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.0 | 33% above |
| 20 week MA | $21.9 | 39% above |
| 50 week MA | $23.3 | 31% above |
| 100 week MA | $20.7 | 48% above |
| 200 week MA | $20.4 | 49% above |
VRDN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
VRDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.62 | $17.6 | +131% |
| 2021 | $17.6 | $21.5 | +22% |
| 2022 | $21.5 | $29.6 | +38% |
| 2023 | $29.6 | $21.8 | -26% |
| 2024 | $21.8 | $19.5 | -11% |
| 2025 | $19.5 | $31.9 | +64% |
| 2026 YTD | $31.9 | $30.5 | -4.4% |
VRDN has the edge over HIMS on returns for 2026, with the stronger performance.